Skip to main content
Sister Publication Links
  • ESG: THE NEW IMPERATIVE
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • COVID-19
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Transformation
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Digital Health
  • Insights
    • ACA 10 Years After
    • Best Practices
    • Special Reports
    • Innovations
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Supply Chain
    • - Hospital at Home
    • - Workplace of the Future
    • - Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • Data Center
    • Data Center Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • MORE +
    • Contact Us
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Safety & Quality
August 27, 2012 01:00 AM

Drug buoys Cleveland company's stem-cell aspiration

Chuck Soder, Crain's Cleveland Business
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print

    Juventas Therapeutics is a drug company competing against stem cell companies. That distinction could give the young Cleveland company a leg up on other businesses trying to hit it big in the regenerative medicine business, according to Juventas CEO Rahul Aras and a few people who follow the industry. Juventas has developed a drug designed to trick the body into sending more stem cells to the site of an injury than it otherwise would, thereby speeding up the healing process. By making a drug, Juventas should be able to sidestep a few big challenges faced by companies developing therapies that use adult stem cells.

    Drugs are easier to make than stem cells, and they tend to be easier to store, according to Dr. Aras and others interviewed for this story. Plus, investors and regulators are more familiar with drugs, which should make it easier for Juventas to raise cash and get its product to market, they said.

    “You get the benefits of regenerative medicine without the complexity of cell therapy,” Dr. Aras said.

    Dr. Aras cites those advantages when speaking with investors. It seems to be working: Juventas in mid-July closed a $22 million Series B financing round led by Triathlon Medical Ventures of Cincinnati and New Science Ventures of New York. The company has raised a total of $35 million since it was spun out from the Cleveland Clinic in 2007.

    As part of the Series B round, the company received an investment from Japan's biggest drugmaker, Takeda Pharmaceutical Co. Dr. Aras described Takeda as a strategic investor that one day could help Juventas take its products to market, possibly via an acquisition or some other partnership. However, the investment didn't give Takeda any exclusive rights to Juventas' products.

    Dr. Aras described the relationship as “a nice way for the two groups to get to know each other better.”

    Of course, Juventas will need to prove that its product, JVS-100, is effective if it is to succeed. It's working on that: The company a few weeks ago started enrolling patients in a Phase II clinical trial designed to test the drug's ability to treat patients with late-stage heart failure. A few months before, it began a similar trial for patients with critical limb ischemia, which is caused when blocked arteries prevent blood from properly flowing to the extremities, often the legs and feet.

    In both cases, JVS-100 is delivered to the site of the injury. The drug contains DNA, which is absorbed into cells in the body. The cells then for two weeks make a protein that acts as a beacon, attracting stem cells to the injured area.

    If Juventas can ace those trials, it will have a big advantage over its competition, according to Jason Napodano, managing director and senior biotechnology analyst for Zacks Investment Research.

    Though he wasn't familiar with Juventas, Mr. Napodano follows several stem cell companies. Some are struggling to obtain FDA approval. Others have had trouble setting up a system to mass produce stem cells or raising enough cash to get their products to market.

    As others in the business noted, both the FDA and investors are more comfortable with drugs than with stem cell products, Mr. Napodano said. Plus, producing a drug “certainly would be a lot cheaper” than making stem cells, he said.

    Some stem cell therapies involve taking bone marrow from a patient, collecting stem cells from the marrow and injecting them back into the patient's body. Other methods involve collecting stem cells from a single donor and then replicating them for use in other patients.

    Dr. Aras said the first method is the most expensive because it involves collecting and purifying stem cells from every patient. While the second method would benefit from greater economies of scale, it is a “much more complicated system” than the one proposed by Juventas, according to Glen Gaughan, a CEO-in-Residence at BioEnterprise Corp., a Cleveland nonprofit that works with health care companies.

    In addition to the challenge of getting stem cells to replicate, it's also hard to store them and to make sure they morph into the right type of cell, said Dr. Gaughan, who before joining BioEnterprise spent about 20 years as a drug discovery scientist for the company that became Bristol-Myers Squibb.

    “It's hard to make these stem cells,” he said. “It's hard to make sure they are what you think they are. It's hard to keep them alive.”

    Drs. Aras and Gaughan expect Juventas' clinical trials to produce data proving that JVS-100 is an effective drug. They cited previous animal studies and Phase I trial data. In that trial, 17 heart failure patients took the drug. Fifteen were still alive after a year, nearly half improved to class II from class III, and some improved to class I. None experienced serious problems deemed related to the drug.

    Though the early data is “quite promising,” B.J. Lehmann doubts the drug will be as effective as therapies that use stem cells. Mr. Lehmann is president and chief operating officer of Athersys Inc., a Cleveland company that aims to commercialize a stem cell therapy that would involve taking stem cells from relatively few donors and mass producing them.

    If the two products turn out to have the same impact on a patient's health, Juventas would have an advantage, Mr. Lehmann said, but he added that the effectiveness of JVS-100 might be restricted by the supply of stem cells in the body. By contrast, companies such as Athersys choose how many stem cells to use, Mr. Lehmann said, adding that Athersys can double one donor's cells in less than 24 hours.

    “You can produce whatever dose level you want to produce,” he said.

    Although Dr. Aras believes Juventas has an edge over its competition, he said he also sees room in the market for several types of regenerative medicine companies.

    Juventas in May moved into 6,200 square feet at Tyler Village in Midtown Cleveland. The new headquarters is many times bigger than the few offices it previously occupied in the Global Cardiovascular Innovation Center, which is across the street from the Cleveland Clinic's main campus.

    Although the company has hired six people since April, it still has just 10 employees, who fill about half of the new space. Juventas is planning to keep hiring, but its biggest expense is the clinical trials, which are run by other organizations.

    The Global Cardiovascular Innovation Center is one of several organizations that have provided key resources and assistance to Juventas over the years, Dr. Aras said. Others include JumpStart Inc. of Cleveland and the Center for Stem Cell & Regenerative Medicine, which is comprised of researchers from Case Western Reserve University, University Hospitals Case Medical Center, the Cleveland Clinic, Athersys and Ohio State University.

    All three of those organizations have received money from the state's Third Frontier economic development program, which is designed to create jobs by financing technology companies and research projects.

    Dr. Aras said he expects those investments will lead to more jobs at Juventas, even if the company eventually is acquired.

    He cited a few situations in which big pharmaceutical companies bought regenerative medicine businesses and decided to keep those companies' employees on board. That's because the small companies not only have technology, but they also have expertise in regenerative medicine, Dr. Aras said.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Patient converses with healthcare interpreter who is visible on a screen in a doctor's office. A medical provider stands off to the right.
    Medical interpreters face high demand, low reimbursement
    Nursing Home covid
    AHCA sounds alarm on nursing home staffing crisis
    Most Popular
    1
    More healthcare organizations at risk of credit default, Moody's says
    2
    Centene fills out senior executive team with new president, COO
    3
    SCAN, CareOregon plan to merge into the HealthRight Group
    4
    Blue Cross Blue Shield of Michigan unveils big push that lets physicians take on risk, reap rewards
    5
    Bright Health weighs reverse stock split as delisting looms
    Sponsored Content
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • COVID-19
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Digital Health
    • Insights
      • ACA 10 Years After
      • Best Practices
      • Special Reports
      • Innovations
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top 25 Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Supply Chain
        • - Hospital at Home
        • - Workplace of the Future
        • - Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • Data Center
      • Data Center Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • MORE +
      • Contact Us
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing